Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

In clinical practice, patients with <i>anaplastic lymphoma kinase (ALK)</i>-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of <i&g...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Pharmaceuticals
المؤلفون الرئيسيون:	Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll, Romana Wass, Elmar Brehm, Gudrun Absenger, Tatjana Bundalo, Peter Errhalt, Matthias Urban, Arschang Valipour
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2020-11-01
الموضوعات:	<i>ALK</i>-positive disease <i>ROS1</i>-positive disease ALK tyrosine kinase inhibitor treatment sequential treatment lorlatinib
الوصول للمادة أونلاين:	https://www.mdpi.com/1424-8247/13/11/371